{
    "clinical_study": {
        "@rank": "163109", 
        "acronym": "AGSPT_PD", 
        "arm_group": [
            {
                "arm_group_label": "AGSPT_10", 
                "arm_group_type": "Experimental", 
                "description": "tablet, 10mg, QD, 7days"
            }, 
            {
                "arm_group_label": "AGSPT_20", 
                "arm_group_type": "Experimental", 
                "description": "tablet, 20mg, QD, 7days"
            }, 
            {
                "arm_group_label": "AGSPT_40", 
                "arm_group_type": "Experimental", 
                "description": "tablet, 20mg x 2, QD, 7days"
            }, 
            {
                "arm_group_label": "Pantoprazole_20", 
                "arm_group_type": "Active Comparator", 
                "description": "tablet, 20mg, QD, 7days"
            }, 
            {
                "arm_group_label": "Pantoprazole_40", 
                "arm_group_type": "Active Comparator", 
                "description": "tablet, 40mg, QD, 7days"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary object: Evaluate Pharmacodynamic property and safety administered S-pantoprazole 10,\n      20, 40mg and Pantoprazole 20, 40mg in healthy male subjects\n\n      Secondary object : Evaluate Dose-response of S-pantoprazole and pantoprazole and compare\n      each dose-response"
        }, 
        "brief_title": "Investigate a Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects", 
        "condition": "Healthy Male Subjects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult healthy males 20 to 45 years at screening\n\n          -  BMI : 19kg/m2 ~ 26 kg/m2\n\n          -  Blood Pressure : \"140 mmHg \u2265 sitting SBP \u2265 90 mmHg, 95 mmHg \u2265 sitting DBP \u2265 50 mmHg\"\n\n        Exclusion Criteria:\n\n          -  Have history of significant hepatic, renal gastrointestinal, pulmonary,\n             musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases\n\n          -  Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer) or\n             surgery (except for Appendectomy, hernia repair) affected the absorption of\n             medications\n\n          -  Have history of GERD, Gastric ulcer, Duodenal ulcer and H.pylori positive\n\n          -  Hypersensitivity reactions to drugs of clinically significant hypersensitivity\n             reactions in the history of benzimidazole (ex: pantoprazole, NSAID, antibiotic)\n\n          -  Have a history of drug abuse\n\n          -  unusual diet affected the absorption, distribution, metabolism, excretion of\n             medications\n\n          -  Subject who treated with any investigational drugs within 90 days before the\n             administration of investigational drug\n\n          -  Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates\n             etc.) within 30days\n\n          -  Previously donate whole blood within 60 days or component blood within 30 days or\n             transfusion within 30 days\n\n          -  Subject who have taken habitually caffeine (caffeine > 5 units/day)\n\n          -  Subject who have drunken habitually (alcohol > 21 units/week, 1 unit = pure alcohol\n             10ml)or who are unable to quit drinking during this study or smoker\n\n          -  Subjects deemed ineligible by investigator based on other reasons"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882296", 
            "org_study_id": "AGSPT_PD"
        }, 
        "intervention": [
            {
                "arm_group_label": "AGSPT_10", 
                "description": "AGSPT 10mg for 7days administration", 
                "intervention_name": "AGSPT_10", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AGSPT_20", 
                "description": "AGSPT 20mg for 7days administration", 
                "intervention_name": "AGSPT_20", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AGSPT_40", 
                "description": "AGSPT 20mg x 2tablet for 7days administration", 
                "intervention_name": "AGSPT_40", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pantoprazole_20", 
                "description": "Pantoprazole 20mg for 7days administration", 
                "intervention_name": "Pantoprazole_20", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pantoprazole_40", 
                "description": "Pantoprazole 40mg for 7days administration", 
                "intervention_name": "Pantoprazole_40", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pantoprazole"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 19, 2013", 
        "number_of_arms": "5", 
        "official_title": "A Block-randomized, Open-Label, Multiple Oral Dosing, Phase I Study to Explore Comparability of the Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "24h pH", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882296"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "(Time(hour) percent when pH >6) / 24(hours)", 
                "measure": "%Time pH>6", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "100-(percent time pH >4)", 
                "measure": "% inhibition time gastric pH\u22644", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Ahn-Gook Pharmaceuticals Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ahn-Gook Pharmaceuticals Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}